Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

Circulation

Volumn 107, Issue 5, 2003, Pages 686-689

  Boerrigter, Guido ^a   Costello Boerrigter, Lisa C ^a   Cataliotti, Alessandro ^a   Tsuruda, Toshihiro ^a   Harty, Gail J ^a   Lapp, Harald ^b   Stasch, Johannes Peter ^c   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

^b Department of Cardiology   (Germany)

^c BAYER AG   (Germany)

Author keywords

Enzymes; Heart failure; Nitric oxide; Pharmacology

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALDOSTERONE; ANGIOTENSIN; GLYCERYL TRINITRATE; GUANYLATE CYCLASE ACTIVATOR; RENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HEART HEMODYNAMICS; HEART OUTPUT; HEART VENTRICLE PACING; KIDNEY BLOOD FLOW; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; CARDIAC OUTPUT; CARDIAC PACING, ARTIFICIAL; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; GLOMERULAR FILTRATION RATE; GUANYLATE CYCLASE; HEART; HEART FAILURE, CONGESTIVE; HEART FUNCTION TESTS; HEMODYNAMIC PROCESSES; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NITROGLYCERIN; PYRAZOLES; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037432180     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000055737.15443.F8     Document Type: Article

References (10)

1. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
2. Moro MA, Russel RJ, Cellek S, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480-1485.
3. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002;99: 8306-8311.
4. Lisy O, Lainchbury JG, Leskinen H, et al. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37:1089-1094.
5. Layland J, Li JM, Shah AM. Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol. 2002;540:457-467.
6. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
7. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
8. Mulsch A, Bara A, Mordvintcev P, et al. Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo. Br J Pharmacol. 1995;116:2743-2749.
9. Arstall MA, Sawyer DB, Fukazawa R, et al. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res. 1999;85:829-840.
10. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Card. 1997;80:111-161.